JAMAL G. MISLEH MD NPI 1174665822

NPI Details

Jamal G. Misleh, MD is a hematology and oncology internal medicine in Newark, DE with 23 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Jamal G. Misleh, MD NPI is 1174665822. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF MIAMI, LM MILLER SCHOOL OF MEDICINE
Graduation Year:2003

The provider's business location address is:

4701 OGLETOWN STANTON RD
SUITE 3400
NEWARK, DE
ZIP 19713-055
Phone: (302) 366-1200
Fax: (302) 366-1700

The NPI 1174665822 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Vincristine sulfate, 1 mg (HCPCS:J9370)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Advance care planning, first 30 minutes (HCPCS:99497)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Injection of drug or substance into vein (HCPCS:96374)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Smoking and tobacco use intensive counseling, 4-10 minutes (HCPCS:99406)
• Declotting of central venous tube (HCPCS:36593)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)

The enumeration date for this NPI number is 2/12/2007 and was last updated on 6/15/2009.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: